ECSP10010029A - HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR - Google Patents

HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR

Info

Publication number
ECSP10010029A
ECSP10010029A EC2010010029A ECSP10010029A ECSP10010029A EC SP10010029 A ECSP10010029 A EC SP10010029A EC 2010010029 A EC2010010029 A EC 2010010029A EC SP10010029 A ECSP10010029 A EC SP10010029A EC SP10010029 A ECSP10010029 A EC SP10010029A
Authority
EC
Ecuador
Prior art keywords
pain
human
growth factor
antibody
nerve growth
Prior art date
Application number
EC2010010029A
Other languages
Spanish (es)
Inventor
Joel H Martin
Lynn Macdonald
Richard Torres
Marc R Morra
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ECSP10010029A publication Critical patent/ECSP10010029A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo o fragmento de unión a antígeno de un anticuerpo humano que se une específicamente a factor de crecimiento de nervio humano (NGF) con una KD de 5 pM o menos, que no reacciona de forma cruzada con neurotrofina-3 (NT-3, y que se une a NGF humano con una KD aproximadamente de 2 a 10 veces mayor que la correspondiente a la unión del anticuerpo o fragmento con NGF de rata o de ratón. Los anticuerpos son útiles para tratar el dolor, que incluye dolor inflamatorio, dolor de incisión post-operatorio, dolor neuropático, dolor de fractura, dolor de fractura osteoporótica, neuralgia post-herpética, osteoartritis, artritis reumatoide, dolor de cáncer, dolor procedente de quemaduras, dolor de articulación de gota, así como enfermedades tales como el carcinoma hepatocelular, el cáncer de pecho y la cirrosis hepática.An antibody or antigen-binding fragment of a human antibody that specifically binds to human nerve growth factor (NGF) with a KD of 5 pM or less, which does not cross-react with neurotrophin-3 (NT-3, and that binds to human NGF with a KD approximately 2 to 10 times greater than that corresponding to the binding of the antibody or fragment with rat or mouse NGF Antibodies are useful for treating pain, including inflammatory pain, pain of post-operative incision, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, burn pain, gout joint pain, as well as diseases such as carcinoma Hepatocellular, breast cancer and liver cirrhosis.

EC2010010029A 2007-08-10 2010-03-10 HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR ECSP10010029A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96422407P 2007-08-10 2007-08-10
US99452607P 2007-09-20 2007-09-20
US6286008P 2008-01-28 2008-01-28
US7925908P 2008-07-09 2008-07-09

Publications (1)

Publication Number Publication Date
ECSP10010029A true ECSP10010029A (en) 2010-04-30

Family

ID=39951432

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010029A ECSP10010029A (en) 2007-08-10 2010-03-10 HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR

Country Status (31)

Country Link
US (3) US7988967B2 (en)
EP (2) EP2572729A3 (en)
JP (1) JP5632744B2 (en)
KR (2) KR101709488B1 (en)
CN (1) CN101827609B (en)
AU (1) AU2008287037B2 (en)
BR (1) BRPI0815370B8 (en)
CA (1) CA2695997C (en)
CO (1) CO6261383A2 (en)
CR (1) CR11298A (en)
CY (1) CY1116072T1 (en)
DK (1) DK2187964T3 (en)
DO (1) DOP2010000054A (en)
EC (1) ECSP10010029A (en)
ES (1) ES2517872T3 (en)
HR (1) HRP20141025T1 (en)
IL (1) IL203558A (en)
MA (1) MA31695B1 (en)
ME (2) ME02239B (en)
MX (1) MX2010001395A (en)
MY (2) MY153781A (en)
NI (1) NI201000021A (en)
NZ (1) NZ583200A (en)
PL (1) PL2187964T3 (en)
PT (1) PT2187964E (en)
RS (1) RS53661B1 (en)
RU (1) RU2473564C2 (en)
SI (1) SI2187964T1 (en)
TN (1) TN2010000059A1 (en)
WO (1) WO2009023540A1 (en)
ZA (1) ZA201000725B (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN102746399B (en) 2002-12-24 2016-03-02 里纳特神经系统学公司 Anti-ngf antibodies and using method thereof
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
KR101709488B1 (en) 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TR201802935T4 (en) 2008-09-19 2018-03-21 Pfizer Stable liquid antibody formulation.
DK2350075T3 (en) 2008-09-22 2014-05-26 Array Biopharma Inc SUBSTITUTED IMIDAZO [1,2B] PYRIDAZINE COMPOUNDS AS TRK-KINASE INHIBITORS
PT3106463T (en) 2008-10-22 2018-05-18 Array Biopharma Inc Substituted pyrazolo[1,5-]pyrimidine compounds as trk kinase inhibitors
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102459337B (en) 2009-05-04 2015-05-20 雅培研究有限责任公司 Anti-nerve growth factor (NGF) antibodies with enhanced in vivo stability
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (en) 2009-07-08 2015-10-07 科马布有限公司 Animal Models and Therapeutic Molecules
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CA2774032C (en) * 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
RU2735545C2 (en) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Macrocyclic compounds as trk kinase inhibitors
JOP20190250A1 (en) * 2010-07-14 2017-06-16 Regeneron Pharma Stabilized formulations containing anti-ngf antibodies
JP6121903B2 (en) 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー Anti-NGF antibodies and uses thereof
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
KR20190112175A (en) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
CN102198272B (en) * 2011-05-27 2013-01-02 北京中科拜克生物技术有限公司 Medicinal composition for promoting fracture union and repairing injured nerves
PT2743348T (en) 2011-08-11 2018-02-23 Astellas Pharma Inc Novel anti-human ngf antibody
BR112014006390A2 (en) 2011-09-19 2017-03-28 Kymab Ltd antibodies, variable domains and chains made especially for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EA034689B1 (en) 2012-04-27 2020-03-06 Милленниум Фармасьютикалз, Инк. Anti-gcc antibody molecule and use thereof to test for susceptibility to gcc-targeted therapy
JO3820B1 (en) * 2012-05-03 2021-01-31 Regeneron Pharma Human antibodies to FEL D1 and methods for their use
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
BR112015003032B1 (en) 2012-08-13 2023-03-28 Genentech, Inc ISOLATED ANTIBODIES, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION AND USE OF THE ANTIBODY
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (en) * 2013-02-08 2017-05-31 アステラス製薬株式会社 Novel anti-human NGF antibody
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
JP6556758B2 (en) * 2014-01-24 2019-08-07 チャーチ、ウィリアム、アール． S. aureus specific antibody, therapeutic method and detection method using the same
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
US11867696B2 (en) 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
CN104910274B (en) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 The neutralizing monoclonal antibody 12C11 and its hybridoma cell strain of anti human nerve growth factor
CN104777311B (en) * 2015-02-12 2016-08-17 北京华安科创生物技术有限公司 The monoclonal antibody of anti human nerve somatomedin hNGF and the immue quantitative detection reagent box of hNGF
CN104774265B (en) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor
AU2016268625B2 (en) 2015-05-22 2022-01-27 Astellas Pharma Inc. Novel anti-human NGF antibody Fab fragment
US20180236032A1 (en) * 2015-08-13 2018-08-23 Merck Patent Gmbh Combination composition comprising fgf-18 compound
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CN112409471B (en) * 2016-04-13 2022-07-29 舒泰神（北京）生物制药股份有限公司 Low-pain nerve growth factor mutant
ES2952056T3 (en) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide
US12123874B2 (en) * 2016-07-18 2024-10-22 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
AU2017366870B2 (en) * 2016-11-29 2024-09-19 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction
EP3558347B1 (en) 2016-12-22 2026-01-21 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
CN114751982B (en) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 Anti-human NGF antibody and its preparation method and use
CN108059676B (en) * 2017-12-28 2020-07-31 未名生物医药有限公司 Anti-human nerve growth factor scFv antibody and preparation method thereof
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108623687A (en) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 Monoclonal antibody of nerve growth factor and coding gene and application thereof
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
EP3833687A1 (en) 2018-08-10 2021-06-16 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Cytokine release syndrome-attenuating dosing strategy for bispecific antibodies to CD3 and CD20
JP2020117502A (en) 2019-01-28 2020-08-06 ファイザー・インク Method of treating signs and symptoms of osteoarthritis
EP3927430A1 (en) 2019-02-18 2021-12-29 Pfizer Inc. Method of treatment of chronic low back pain
EP3947464A4 (en) * 2019-04-05 2023-01-11 B-Portal Biologics, Inc. FUSION CONSTRUCTIONS AND THEIR USES
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN113924315B (en) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 anti-beta-NGF nano antibody and application thereof
WO2021136841A2 (en) * 2019-12-31 2021-07-08 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain
CN113527482B (en) * 2020-04-17 2023-07-21 珠海泰诺麦博制药股份有限公司 Antibody against human nerve growth factor
CN113527483B (en) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
EP4157881A4 (en) * 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN116003590A (en) * 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 Anti-NGF antibody and its antigen-binding fragment, its preparation method and application
EP4217388A1 (en) 2020-09-28 2023-08-02 MedImmune Limited Compounds and methods for treating pain
CN114470189B (en) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Application of NGF antibody in CIPN pain
US20240117072A1 (en) * 2020-12-18 2024-04-11 Bioardis, Llc Fap binding molecules and uses thereof
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
CN115725684A (en) * 2021-08-28 2023-03-03 达石药业(广东)有限公司 A kind of anti-NGF drug cell proliferation inhibitory activity test method
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20250340626A1 (en) 2021-12-16 2025-11-06 Intervet Inc. Caninized antibodies to human ngf
CN114397453B (en) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 Detection kit for novel coronavirus mutant strain and application thereof
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514294A (en) * 1894-02-06 Governor
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
ES2157903T3 (en) * 1991-07-10 2001-09-01 Regeneron Pharma METHODS OF TREATMENT OF MOTOR NEURONS DISORDERS USING MEMBERS OF THE BDNF / NT-3 / NGF MOLECULES FAMILY.
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
IT1306704B1 (en) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en) 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
WO2005056601A2 (en) * 2003-12-05 2005-06-23 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AUPR256601A0 (en) * 2001-01-17 2001-02-08 Silverbrook Research Pty. Ltd. An apparatus (AP29)
CA2975521A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
CA2496419A1 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7252822B2 (en) 2002-10-08 2007-08-07 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (en) * 2002-12-24 2016-03-02 里纳特神经系统学公司 Anti-ngf antibodies and using method thereof
BRPI0407375A (en) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Methods for treating pain by administering a neural growth factor antagonist and a nsaid and compositions containing same
CN1849138B (en) * 2003-07-15 2011-11-30 安姆根有限公司 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
PL1732949T3 (en) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1846451B1 (en) * 2005-01-24 2013-05-15 Medimmune Limited Human antibodies against human ngf
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
AU2006283194B9 (en) * 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
US9789161B2 (en) 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
RS52176B (en) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
KR101709488B1 (en) 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. High affinity human antibodies to human nerve growth factor
CN102459337B (en) 2009-05-04 2015-05-20 雅培研究有限责任公司 Anti-nerve growth factor (NGF) antibodies with enhanced in vivo stability

Also Published As

Publication number Publication date
ME00977B (en) 2012-06-20
JP5632744B2 (en) 2014-11-26
EP2187964A1 (en) 2010-05-26
US20090041717A1 (en) 2009-02-12
CN101827609A (en) 2010-09-08
CN101827609B (en) 2014-03-12
KR101709495B1 (en) 2017-02-23
TN2010000059A1 (en) 2011-09-26
JP2010535509A (en) 2010-11-25
DOP2010000054A (en) 2010-03-15
ME02239B (en) 2015-04-30
RU2010108525A (en) 2011-09-20
PL2187964T3 (en) 2015-03-31
CA2695997A1 (en) 2009-02-19
US7988967B2 (en) 2011-08-02
US8613927B2 (en) 2013-12-24
BRPI0815370B8 (en) 2021-05-25
CA2695997C (en) 2016-11-22
KR101709488B1 (en) 2017-02-24
AU2008287037A1 (en) 2009-02-19
KR20150125735A (en) 2015-11-09
MY161564A (en) 2017-04-28
KR20100058537A (en) 2010-06-03
CR11298A (en) 2010-03-23
ZA201000725B (en) 2011-06-29
MY153781A (en) 2015-03-13
BRPI0815370B1 (en) 2020-10-20
EP2187964B1 (en) 2014-10-08
MA31695B1 (en) 2010-09-01
IL203558A (en) 2014-03-31
PT2187964E (en) 2015-01-14
SI2187964T1 (en) 2015-01-30
US20120164688A1 (en) 2012-06-28
EP2572729A2 (en) 2013-03-27
NZ583200A (en) 2012-03-30
CO6261383A2 (en) 2011-03-22
AU2008287037B2 (en) 2013-10-10
MX2010001395A (en) 2010-03-10
ES2517872T3 (en) 2014-11-04
BRPI0815370A2 (en) 2015-02-10
RS53661B1 (en) 2015-04-30
NI201000021A (en) 2010-07-27
US8148107B2 (en) 2012-04-03
CY1116072T1 (en) 2017-02-08
HRP20141025T1 (en) 2015-01-02
DK2187964T3 (en) 2015-01-12
HK1144379A1 (en) 2011-02-18
WO2009023540A1 (en) 2009-02-19
EP2572729A3 (en) 2013-06-05
US20110256587A1 (en) 2011-10-20
RU2473564C2 (en) 2013-01-27

Similar Documents

Publication Publication Date Title
ECSP10010029A (en) HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR
CY1119290T1 (en) CLAUDIN-18 MONOCLONE ANTIBODIES FOR CANCER TREATMENT
AR106570A1 (en) ANTI-PSMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN PSMA AND CD3, AND USES OF THESE
GT201200271A (en) PROTEINS THAT JOIN TNF-A
CO2018014325A2 (en) Specific antibodies for hyperphosphorylated tau and its methods of use
BR112016030686A2 (en) humanized anti tau antibodies
PE20191661A1 (en) INHIBITORS OF TGF BETA1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
AR080513A1 (en) CD37 UNION MOLECULES AND THEIR IMMUNOCATE PLAYERS
BR112021023295A2 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha
BR112012022102A2 (en) a-beta binding polypeptides.
BR112021008060A2 (en) Polypeptide, anti-ctla4 antibody or antibody fragment, immunoconjugate, pharmaceutical composition, single dose of pharmaceutical composition, method of treating cancer, and, kit for diagnosis or treatment
BR112012032991A2 (en) mouse expressing a hybrid light chain immunoglobulin.
BR112015008376A2 (en) drug-protein conjugates
BR112017009264A2 (en) epitope binding protein or fragment thereof and heterodimeric immunoglobulin or fragment thereof
AR096015A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES
CO7250445A2 (en) St2 antigen binding proteins
PE20141162A1 (en) ANTI-IL-23 ANTIBODIES
BR112016013347A2 (en) anti-il-33 neutralizing human monoclonal antibody
PE20141659A1 (en) ANTI-VGF SINGULAR VARIABLE DOMAINS FUSED WITH FC DOMAINS
EA201691027A1 (en) APLNR MODULATORS AND THEIR APPLICATION
CO6270341A2 (en) LINKED MOLECULES THAT INCLUDE AN PORTION OF ANTIGEN UNION THAT JOINS THE NEO-EPITOPE C3B MODULATING THE COMPLEMENT COMPONENT
MX2009009450A (en) He4 monoclonal antibodies and methods for their use.
NZ594682A (en) Fully human antibodies specific to cadm1
CY1116313T1 (en) ANTIBODIES AGAINST IL-25
BR112013001062A2 (en) humanized antibodies targeting the cadherin-11 ec1 domain and related compositions and methods